Discontinuation report ARIMIDEX
| Report ID | 257278 |
| Drug Identification Number | 02224135 |
| Brand name | ARIMIDEX |
| Common or Proper name | Nom commun ou nom propre - English |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | ANASTROZOLE |
| Strength(s) | 1MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Taille de l’emballage - English |
| ATC code | L02BG |
| ATC description | HORMONE ANTAGONISTS AND RELATED AGENTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2020-01-01 |
| Actual discontinuation date | 2021-01-01 |
| Remaining supply date | 2022-01-01 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Renseignements sur l’approvisionnement restant - English |
| Company comments | Commentaires de l’entreprise - English |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-09-02 | French | Compare |
| v1 | 2025-09-02 | English | Compare |
Showing 1 to 2 of 2